Cost, quality of life and outcome measures in ovarian cancer.
As research into cancer intensifies and treatments proliferate, life-interval gained is no longer a question of simply measuring time. Ovarian cancer patients, especially, have benefited from efforts to develop feasible screening processes and the new treatment modalities for this type of cancer. Within the last decade, medicine has come to realize that survival intervals and cure rates are useless to patients if they cannot retrieve out of the process at least some aspects of their lives before cancer and for as long a period of time as possible. This article focuses on measuring and assessing the effects of treatment in terms of outcome and quality of life from the patient's perspective. Medicine as a science, and being a science, has not been comfortable in taking into account intangibles when assessing its own performance and success rates. However, the roles of caregivers and health providers have been rapidly evolving from that of treating the disease to treating the patient, and often the patient's family, with all that implies.
Abbas
F M
FM
Gynecologic Oncology, Sinai Hospital, Baltimore, MD 21215, USA.
Sert
M B
MB
D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D005260:Female; D006302:Health Services Research / Q000191:economics*; D006801:Humans; D010043:Outcome and Process Assessment, Health Care; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000191:economics* / Q000451:nursing / Q000628:therapy; D011788:Quality of Life; D016896:Treatment Outcome